The ability to diagnose and treat prion diseases is limited by our current understanding of the conversion process of the protein from healthy to harmful isoform. Whereas the monomeric, benign species is well characterized, the misfolded conformations responsible for infectivity and neurodegeneration remain elusive. There is mounting evidence that fibrillization intermediates, or protofibrils, but not mature fibrils or plaques, are the pathogenic species in amyloid diseases. Here, we use molecular dynamics to simulate the conversion of the prion protein. Molecular dynamics simulation produces a scrapie prion protein-like conformation enriched in ␤-structure that is in good agreement with available experimental data. The converted conformation was then used to model a protofibril by means of the docking of hydrophobic patches of the template structure to form hydrogen-bonded sheets spanning adjacent subunits. The resulting protofibril model provides a nonbranching aggregate with a 31 axis of symmetry that is in good agreement with a wide variety of experimental data; importantly, it was derived from realistic simulation of the conversion process.
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T he prion protein (PrP) is a cell-surface glycoprotein that is bound to the plasma membrane of neuronal cells by a glycosylphosphatidylinositol anchor (1) . PrP has been implicated in various transmissible spongiform encephalopathies (TSEs) including Creutzfeldt-Jakob disease, fatal familial insomnia, Gerstmann-Straussler-Scheinker disease, Kuru in humans, scrapie in sheep, and bovine spongiform encephalopathy in cattle (2, 3) . These diseases involve partial unfolding of the monomeric, cellular prion protein (PrP C ) and its subsequent misfolding to the scrapie isoform (generically denoted here as PrP Sc ). The latter form can, but does not always, aggregate to form amyloid plaques in the brain (4) . Whereas the structure of fragments of hamster, mouse, bovine, and human PrP C have been well characterized by NMR (5-9), high resolution structures of PrP Sc aggregates remain elusive. The two isoforms of PrP can be differentiated by secondary structure: PrP C is largely helical (47% ␣-helix, 3% ␤-structure) whereas PrP Sc is enriched in ␤-structure (10, 11) . The observed secondary structure content of PrP Sc varies from experiment to experiment, partly because there are multiple forms and lengths of PrP Sc , yielding a range of 17-30% ␣-helix and 43-54% extended structure (10) (11) (12) . PrP C can be distinguished from PrP Sc also based on its ability to be proteolytically cleaved by proteinase K; PrP C is completely digested by proteinase K, whereas PrP Sc is only partially digested and termed proteinase K resistant (PrP-res) (11, 13, 14) .
TSE are one among many types of neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Parkinson's disease, and familial amyloid polyneuropathy that exhibit highly structured aggregates (14, 15) . Each of these diseases is linked to protein material that has partially unfolded, misfolded, and aggregated; as with TSE, the detailed structure of the causative agent is unknown. Despite the structural dissimilarity between the soluble proteins and peptides that adopt alternate ␤-structure-rich aggregates, they may share a common mechanism of pathogenesis (16, 17) . To go from a soluble protein to a misfolded conformer that forms large complex deposits, the proteins are believed to first aggregate on a smaller scale and then progress into protofibrils before forming more ordered rigid fibrils. There is a growing body of evidence that soluble fibrillization intermediates are the neurotoxic species, not amyloid fibrils and plaques (16) (17) (18) (19) (20) . Thus, investigations of the structural properties of prefibrillar aggregates for any one of the neurodegenerative diseases may have implications for the entire class of diseases. In the case of TSE, infectivity further complicates the situation. As with the neurotoxic species, infectious oligomers of PrP Sc seem to be smaller, intermediary aggregates, and recent data indicate that the infectious and neurotoxic species are different (20) .
Understanding Motivated by experimental results from the Caughey group (21), we performed simulations of Syrian hamster PrP, residues 109-219 (5), with the D147N mutation (hamster numbering is used throughout this article). They showed that mutations of either of the two aspartic acids (Asp-144 and Asp-147) in helix A (Fig. 1) to asparagine increased the efficiency of conversion from PrP C to PrP Sc 2-to 3-fold compared with wild-type PrP C ( Fig. 1) (21) . Here, we describe the dynamic behavior of D147N in water at both neutral and low pH levels. The D147N mutation disrupted the native conformation of the N-terminal residues 109-170. In particular, in the low pH trajectory, the protein underwent a conformational change resulting in a significant increase in extended secondary structure (similar to the extended nature of ␤-strands). By using a structure from this ensemble, we modeled a prion aggregate that agrees with electron microscopy (EM) data from in vitro infectious Syrian hamster and mouse PrP two-dimensional protofibril crystals (24) . Other experimental results such as changes in PrP C antibody binding sites (25, 26) , PrP Sc selective epitopes (27) , differential proteinase K digestion (13, 28) , fiber diffraction (29), solid-state NMR (30) (31) (32) , and peptide binding studies of PrP Sc (33) (34) (35) are consistent with our model.
Methods
To simulate the dynamic behavior of prion fragments, an in-house version of the program ENCAD (36) was used. All protein atoms were included, and the protein was solvated by explicit water molecules. The protein force field, water model, and procedures have been described in detail (37, 38) . The fragment of the NMR structure of Syrian hamster PrP C (5) (1B10, structure no. 4, residues 109-219) was mutated in ENCAD and then used as the starting conformation. Simulations were run for 20 ns at 25°C, at neutral and low pH levels with the disulfide bond (residues 179-214) intact. A 2-fs time step was used for integration of the equations of motion. An 8-Å forceshifted nonbonded cutoff was used, and the nonbonded list was updated every five steps. Structures from the simulations were saved every 0.2 ps for analysis.
To identify populated conformational states in each simulation, all-by-all comparisons of the C␣ rms deviations of structures were performed (39, 40) . The 8-ns structure of the low-pH simulation was used as a representative conformation of the most populated cluster to model prion protofibril formation. All images were produced by using MIDASPLUS (University of California, San Francisco) software (41) except Fig. 4 b and c, which were produced by using VMD software (42) .
Results and Discussion
Conversion of PrP C 3 PrP Sc . Both the neutral and low pH simulations of the D147N mutant yielded structures that deviated significantly from the starting NMR structure. Conformational clustering was used to locate ensembles of similar structures (39, 40) , which were then inspected for changes in secondary structure. In the low-pH simulation, there was a well populated state from 6 to 20 ns with an average C␣ rms deviation of 5.20 Å from the NMR structure. In contrast, simulations of the wild-type Syrian hamster protein at neutral pH give an average C␣ rms deviation of 2.1 Å (43), with an increase in the helical content, as expected based on CD experiments (23) . At low pH levels, the extended structure increased from 6 to 37 residues (5% 3 34%), and the helical structure decreased from 43 to 37 residues (48% 3 41%). The following residues were involved in extended ␤-sheet-like structure: 114-122, 125-127, 129-133, 135-140, 143, 157-165, 172, 174, 198, and 199. The core of the ␤-structure was a three-stranded sheet, E1-E3, and an isolated strand, E4 (Fig. 1) . E1 (residues 116-119) added to the N-terminal side of the native two-stranded ␤-sheet (Fig. 1b) . S1 and S2 from the NMR structure (residues 129-131 and 161-163) became elongated and are relabeled as E2 (residues 129-132) and E3 (residues 160-164), respectively. E4 designates a new extended region (residues 135-140) near helix A. Thus, the ␤-structure increased and the helical structure decreased at low pH levels, consistent with experimental studies showing that the hallmark of PrP C to PrP Sc conversion is a significant increase in extended structure and a decrease in helical structure (10) (11) (12) .
The increase in efficiency of the conversion of the protein in vitro (21) was expected to be attributed to the disruption of a proposed intrahelical salt bridge between Asp-147 and Arg-151 (44). Although we were surprised to find that helix A was maintained in our simulation [because we have seen disruptions of the helix in past simulations (43, 45) ], we have also found that the Asp-147 to Arg-151 salt bridge is not critical to the stability of helix A. In agreement with our findings, Caughey and coworkers (21) found that this mutation did not substantially destabilize PrP; however, the mutation may alter the unfolding pathway of PrP or a binding event preceding conversion. Also, recent studies of the helix A region suggest that it may not unfold during conversion (46) .
The increase in extended structure at the N terminus is consistent with a wealth of data implicating this region in conversion (25, 47, 48) . In particular, residues 90-120 are antigenically accessible in PrP C and encrypted in PrP Sc (25) . In contrast, helix C is accessible to antibody in both forms. In agreement with experimental data, the unstructured N terminus in PrP C adopted ␤-structure in the simulation, whereas helix C remained unchanged through the conversion. Some residues involved in the new ␤-structure have been mapped to specific N-terminal residues of PrP peptides by solid-state NMR, in particular residues 109-122 (30) . Residues 109-122 encompass the E1 region in our model, which supports our finding that the hydrophobic N-terminal residues increase the extended structure of PrP by backbone hydrogen bonding to the preexisting ␤-sheet. Experimentally, this region prefers extended conformations to helical conformations under certain conditions (30, 31) , and it can take on more than one type of extended form (29) . In addition, a peptide from this portion of the sequence (residues 106-126) is neurotoxic (19, 49) . More recently, conversion of residues 114, 120, 129, and 133 from ␣ 3 ␤ has been seen in an engineered, triple-mutant PrP peptide (residues 90-144, of these Met-129 is ␤ in PrP C ) by solid-state NMR (32) . In our converted model, all of these residues are involved in the new sheet. The dominant conformational cluster observed in the low pH trajectory is one of perhaps many PrP Sc -like structures that could account for the strain-dependent differences in ␤-structure or packing leading to different aggregate morphologies that have been detected experimentally (20, (50) (51) (52) . Sc results in an increase in exposed hydrophobic residues, which were docked together in two 8-ns structures; the hydrophobic N-terminal E1 strand was docked to the hydrophobic E4 strand and aligned by interstrand backbone hydrogen bonding (Fig. 2a) . Propagation of the protofibril occurred by means of incorporation of monomers via identical interfaces in which isolated E4 was connected to the three-stranded sheet, forming a continuous four-stranded sheet. In this way, the E1:E4 interface formed a spiraling protofibril with a 3 1 axis of symmetry (Fig. 2 a and b) . Preliminary simulations of the hexamer lead to further increases in the ␤-structure and optimization of the hydrogen bonding (unpublished results).
As with experimental fibrils, the model is nonbranching (53, 54) with two oligomerization sites that permit the addition of subunits only in the direction of the fiber axis. In agreement with various experimental results, this protofibril has exposed glycosylation sites (24) and an exposed PrP Sc epitope (27) (Fig. 2d) , and the N and C termini are accessible for partial proteinase K digestion (13, 28) with a protected inner core of more tightly packed extended strands (55).
In Fig. 2c , the sequence of a PrP-derived peptide (residues 113-141) that inhibits scrapie formation is shown in green (33). Given our model, the peptide should span both oligomerization sites. Inhibition drops if a peptide complementary to only one of our two interfaces (E1 or E4) is used (33, 34) . The addition of a peptide spanning both regions may form a dead end by binding to either end of the protofibril.
Peptides corresponding to residues 166-179 and 200-223 also inhibit conversion of PrP C to PrP Sc (35) . In our model, residues 166-179 are in the loop extending from E3 to the cysteine residue in helix B, and residues 200-223 comprise helix C (truncated at 219, Fig. 1 ). In the protofibril model, the 166-179 loop makes packing interactions with the interface formed by two subunits underneath it. The 200-223 region makes packing interactions with its N terminus (residues 109-110), residues 166-168 of the adjacent subunit, and the subunit directly below. In examining our aggregate model, it seems that these peptide inhibitors function by sterically blocking packing interactions necessary for PrP C binding, as well as limiting access to the oligomerization site.
Because of the conformational differences between PrP C and PrP Sc , antibodies have been used to map the surfaces of the two distinct forms of the protein, as mentioned above. A PrP Cselective antibody, D18, which binds to residues 132-156 (magenta in Fig. 2c ) (26) , potently blocks conversion and even clears existing PrP Sc (56, 57) . This epitope undergoes only minor structural changes as a result of in silico conversion (see Fig. 1 ). Binding to PrP C would prevent recruitment into the fibril by blocking interfacial residues. Residues 134-140 are obstructed by the E1:E4 interface in the profibril model, and the remaining residues in the epitope are buried such that the antibody would only be able to recognize the protofibril at one of two oligomerization sites (the leading E4 edge). This could lead to low estimates of PrP Sc binding but could possibly contribute to clearance of aggregates in vivo. Schwarz et al. (58) recently took the immunization approach a step further by inducing active immunity to scrapie in mice by administering a peptide corresponding to the neurotoxic portion of the protein (residues 106-126).
Similarly, a PrP Sc -selective antibody binding site (27) supports our protofibril model (Fig. 2d) . This discontinuous epitope, composed of residues 142-148, 162-170, and 214-226, is not formed in PrP C or in current and previous (43, 45) monomeric PrP Sc -like structures from MD. However, in the protofibril, all regions are in close proximity, with the 142-148 region joining the other two segments from an adjacent subunit. The epitope requires at least two subunits for its formation, and the addition of multiple subunits creates a continuous epitope spanning the length of each of the three faces of the protofibril. In addition, residue 139 seems to be important in the mouse-hamster species barrier (59) , and this residue is on the putative PrP C binding surface of the protofibril model (Fig. 2) .
Electron crystallography studies of two-dimensional PrP crystals by Wille et al. (24) have provided medium resolution images of an intermediary PrP oligomer. By using our modeled protofibril, we are able to reproduce their 7-Å resolution images. The PrPs used in their experiment were a mixture of di-, mono-, and nonglycosylated forms. We diglycosylated each subunit at the known glycosylation sites, residues 181 and 197, to unify our constructs (Fig. 3a) .
Our protofibril has a 3-fold screw axis (which twodimensionally would be reduced to 3-fold symmetry), and the EM data suggest either 3-or 6-fold symmetry. By superimposing two of our 3-fold protofibrils rotated 60°with respect to one another around the fiber axis (Fig. 3) , Ϸ6-fold symmetry is obtained. The EM images from Wille et al. (24) shown in Fig. 3 are difference maps between two PrP constructs: PrP27-30 (residues 90-231) with variable glycosylation and PrP106 (residues 90-140, 177-231), which is consistently diglycosylated. The statistical differences are highlighted and represent the location of the internal deletion residues of PrP106 in PrP27-30 (magenta in Fig. 3 c, e, and f ) and the differential glycosylation (cyan in Fig.  3d ) (24) . The central dark areas were proposed to be the N terminus of PrP with its negatively charged residues involved in complexation of the heavy metal cations used for staining (24) . To mimic this effect in Fig. 3 c, d , and f, residues 109-170 were black to produce a positive density whereas the remaining residues were white to produce a negative density. By using the same color scheme for deletion residues 141-176 and sugars as the experiment, the modeled protofibril produced similar images.
There is strong evidence to suggest that the dominant hydrogen-bonding pattern in fibrils is parallel to the fiber axis, such that the extended strands are oriented perpendicular to the axis (14, 60) . Bona fide prion fibrils are obtained by subjecting brain material to detergents and limited proteolysis (54, 60) , which are then subjected to fiber diffraction. In our model, extended sheets spiral about the fibril axis, tilting away from the axis at Ϸ45°, and may represent intermediates en route to the fibrillar state, as expected for protofibrils. In fact, recent attempts to model fibrils with hydrogen-bonding patterns parallel to the fiber axis by using ␤-sheets perpendicular to the fiber axis poorly reproduce the experimental constraints, which suggests that other models may be necessary for fibrils as well (61) .
There is mounting evidence that amyloid fibrils are not required for neurotoxicity and instead may be relative inert dumping grounds for protein (20) . Instead, the lower molecular weight, fibrillization intermediates are believed to be the neurotoxic species in various amyloid diseases (16, 17, 62) and responsible for PrP infectivity (20) . Unfortunately, however, the greatest body of knowledge on oligomer structure is based on mature insoluble fibrils, and we lack firm structural information for protofibrils. We are investigating the possible conversion of our PrP protofibril model to a fibril by means of MD simulation for comparison with the cross ␤-structure observed experimentally in fibrils (unpublished results).
The dimensions of our protofibril model fit those imposed by x-ray diffraction and EM studies of PrP and other amyloidforming proteins. The unglycosylated form has a diameter of 65 Å, and that of the EM protofibril is Ͻ69 Å (Fig. 4) . This diameter is large compared with fibrils formed by transthyretin, the A␤ peptide, and the SH3 domain, which are typically 20-30 Å (63). However, these proteins and peptides are smaller than PrP and composed entirely of ␤-sheets, unlike PrP Sc . The inner extended sheet core of our PrP protofibril (strands E1, E2, E3, and E4) has a diameter of 35 Å (Fig. 4) , which is comparable with the all-␤-transthyretin fibril at 33 Å (64). But, it is also possible that the dimensions change in the protofibril 3 fibril process.
Conclusions
By using a prion conformation derived from a low-pH MD simulation, we modeled a protofibril with characteristics consistent with experimentally derived protofibrils. It was previously stated that the only structure capable of fitting the constraints proposed by the EM data was a ␤-helix (24) . Variations on the cylindrical ␤-sheet model proposed by Perutz et al. (65) and on ␤-helix structures from soluble nonamyloid-forming proteins may be viable models with respect to the cross ␤-hydrogen bonding pattern; however, recent vibrational Raman optical activity experiments of reduced PrP conformers capable of fibrillization yield spectra similar to flat ␤-sheet proteins, not ␤-helix (66) . Here, we have shown that a less complex conversion than that required for formation of a ␤-helix is observed directly by means of MD simulations and that the resulting converted conformation is capable of oligomerization into an analogously tightly packed protofibril in good agreement with the available experimental data. With reasonable protofibril models at hand, we can begin to investigate the effects of intermolecular interactions on aggregate conformations and provide plausible mechanisms and sites for drug action.
